44
Participants
Start Date
May 31, 2012
Primary Completion Date
November 30, 2012
Study Completion Date
December 31, 2012
IMO-3100 at 0.16 mg/kg
IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
Saline for Injection
Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
IMO-3100 at 0.32 mg/kg
IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
Derm Research Center of New York, Stony Brook
Atlanta Dermatology, Vein & Research Center, PC, Alpharetta
Dermatologic Surgery Specialists, Inc., Macon
Florida Center for Dermatology, P.A, Jacksonville
DermResearch PLLC, Louisville
Indiana Clinical Trials Center, PC, Plainfield
Center for Clinical Studies, Webster
J & S Studies, College Station
University of Utah, Dermatology, Salt Lake City
Oregon Dermatology and Research Center, Portland
Tufts Medical Center, Boston
Mass General Hospital Clinical Unit for Research Trials in Skin, Boston
Clinical Partners, Inc, Johnston
Lead Sponsor
Idera Pharmaceuticals, Inc.
INDUSTRY